Baxter Announces U.S. FDA Clearance Of Novum IQ Syringe Infusion Pump With Dose IQ Safety Software
Furthers Baxter's continued innovation in medication delivery and management
Integrates Baxter's decades of leadership in infusion therapy with innovative digital health solutions to build on the company's
Hepion Pharmaceuticals Announces Initiation Of Phase 2b ‘ASCEND-NASH’ Trial
Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic
Amgen Announces Topline Data From Lumakras Phase 3 Trial In Non-small Cell Lung Cancer Met Its Primary Endpoint
LUMAKRAS Met Primary Endpoint of Progression-Free Survival, Demonstrating Superiority Over Standard of Care Docetaxel Chemotherapy, in KRAS G12C-Mutated Non-Small Cell Lung Cancer
Detailed Data to be Presented
Inari Medical Announces Randomized Controlled Trial Evaluating Clinical Outcomes Of The ClotTriever System In Deep Vein Thrombosis
IRVINE, Calif., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) ("Inari") a medical device company with a mission to treat and transform the lives of patients suffering from venous and otherIRVINE, Calif., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc.
Outlook Therapeutics Shares Pop After Filing US Application For Its Lead Eye Disease Candidate
Outlook Therapeutics Inc (NASDAQ:OTLK) has re-submitted its marketing application to the FDA, seeking approval for ONS-5010 for wet age-related macular degeneration…
OKYO Pharma Plans Q4 2022 IND Filing Of OK-101 To Treat Dry Eye Disease With Subsequent Phase 2 Initiation
OK-101 to treat ocular diseases, including Dry Eye Disease (DED), uveitis, allergic conjunctivitis, and ocular pain.
Successful pre-IND meeting with FDA in Q1 2022 and novel speed to market potential.
IND
Curis Resumes Enrollment In Monotherapy TakeAim Leukemia Study, Combo Phase Still Under Partial Hold
The FDA has notified Curis Inc (NASDAQ: CRIS) to resume enrollment of additional patients in the monotherapy phase of the TakeAim Leukemia study of Emavusertib.
Jaguar Health Announces Submission Of IND Application To FDA For Drug Candidate For The Relief Of Diarrhea From Cholera
Jaguar is concentrating financial and management resources on two near-term late-stage clinical events